CervoMed Q1 Net Loss $8.0M; Advances DLB Phase 3 Trial Planning
CervoMed reported a Q1 2026 net loss of $8.0 million, an increase from $4.9 million in Q1 2025, with cash and equivalents decreasing to $12.9 million, providing a runway into Q3 2026. The company made significant progress in its clinical programs, finalizing the design for its planned Phase 3 trial of neflamapimod in Dementia with Lewy Bodies (DLB), subject to financing, and expects to initiate it in H2 2026. Positive MRI data and biomarker analyses for neflamapimod in DLB were presented at AAN and AD/PD 2026, respectively, reinforcing its potential as a disease-modifying treatment. Enrollment for the Phase 2a trial in nfvPPA is complete in the US, and neflamapimod was selected for the EXPERTS-ALS platform.
Key Highlights
- Q1 2026 Net Loss: $8.0 million, compared to $4.9 million in Q1 2025.
- Cash Position: $12.9 million as of March 31, 2026, down from $20.9 million on Dec 31, 2025.
- Cash Runway: Expected to fund operations into Q3 2026.
- R&D Expenses: $5.1 million in Q1 2026, up from $4.8 million in Q1 2025.
- G&A Expenses: $3.0 million in Q1 2026, up from $2.4 million in Q1 2025.
- DLB Phase 3 Trial: Planned for initiation in H2 2026, subject to financing.
- nfvPPA Phase 2a Trial: US enrollment completed with 19 patients randomized.
- European Patent: Issued in March 2026, expiring in 2040.
Price Impact
More from CRVO